Acute diarrhea in adults: urgency of the problem and new

• Nikolay D. Yushchuk
• Andreev D.N.
• Kucheryavyy Yu.A.

Abstract

To date, acute diarrhea (AD) in aduLt popuLation is one of the Leading heaLth probLems in both deveL­oped and developing countries. Each year there are approximateLy 2.2 biLLion cases of AD worLdwide. The AD-associated dehydration is a Leading cause of mortaLity in this cohort of patients resuLting in 1.3-2.5 miLLion deaths each year. The management of AD is based on the pathogenetic treatment, rehydration ther­apy and symptomatic treatment aiming at restoring of pathophysiologic mechanisms. RacecadotriL is a new symptomatic antidiarrheaL drug exerting a direct suppressive effect on the intestinaL water and eLectroLyte hypersecretion caused by pathogenic effects of viruses and bacteriaL toxins. The efficacy of racecadotriL in the treatment of AD in aduLt patients has been demonstrated in a number of randomized controLLed cLini­caL studies and severaL meta-anaLyses. Treatment with racecadotriL was characterized by its cLear superiority over pLacebo in terms of regression of diarrhea duration and amount and weight of Loose stooL. Compared to reference therapy (Loperamide), there were no significant differences in treatment effectiveness. However, it was found that treatment with racecadotriL was associated with Lower rates of constipation. A pharmacoeconomic evaLuation reveaLed superiority of racecadotriL over Loperamide.

Keywords:acute diarrhea, acute intestinal infections, symptomatic therapy, loperamide, racecadotril, Hidrasec

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)